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Patients with cirrhosis seek improvement in their symptoms, functioning, quality of life, and satisfaction with the care
they receive. However, these patient-reported outcomes (PROs) are not routinely measured for clinical care, research, or
quality improvement. The members of the American Association for the Study of Liver Diseases Practice Metrics Com-
mittee, charged with developing quality indicators for clinical practice, performed a scoping review of PROs in cirrhosis.
The aim is to synthesize a comprehensive set of PROs for inclusion into a standard patient-centered outcome set. We
searched Medline, Embase, the Cumulative Index to Nursing and Allied Health Literature, PsycINFO, and the Cochrane
Trial Library since inception, with ﬁnal searches run between April 20 and June 1, 2017. Studies were included if they
reported the construction and/or validation of a PRO instrument for patients with cirrhosis or if they assessed the clinical
(case-mix) variables determining responses to established PRO scales. Eleven studies were selected that yielded 259 items
speciﬁc to patients with cirrhosis. After removing duplicates, 152 unique items were isolated. These items were consoli-
dated into seven domains: physical symptoms, physical function, mental health, general function, cognition, social life, and
satisfaction with care. The seven domains included 52 subdomains (e.g., physical domain, abdominal pain subdomain).
Twelve variables were identiﬁed that independently modiﬁed established PRO scales. These included clinical factors
(severity of liver disease and its complications, medication burden, and comorbidities), speciﬁc PROs (cramps, pruritis),
and surrogate outcome measures (falls, hospitalization). Conclusion: This scoping review identiﬁed and categorized a large
existing set of PRO concepts that matter to patients with cirrhosis; these outcomes may now be translated into usable
measures both for the assessment of the quality of cirrhosis care in clinical practice and to perform research from the
patient’s perspective. (HEPATOLOGY 2018;67:2375-2383).
The prevalence of cirrhosis in the United Stateshas almost doubled in the last decade, result-ing in a substantial rise in its associated mor-
bidity and mortality.(1,2) As many as half of patients
with cirrhosis develop clinical complications, including
variceal hemorrhage, ascites, hepatic encephalopathy,
and hepatocellular carcinoma. The health burden of cir-
rhosis is ampliﬁed by its dramatic impact on patients’
health-related quality of life (HRQOL), resulting from
a range of physical, psychological, and social stressors
engendered by cirrhosis and its treatment.
Ensuring that patients with serious illness receive
patient-centered care is a fundamental goal of medical
care. For this care to be patient-centered, it must be
aligned with what matters to the patients. Despite the
realization that patient-reported outcomes (PROs) are
important to patients, current quality improvement
efforts rarely assess PROs. One explanation underlying
this disconnect is lack of standardized PROs that may
serve as benchmarks for quality measurement and
improvement in cirrhosis.
To address this gap, and under the auspices of the
Practice Metrics Committee of the American Associa-
tion for the Study of Liver Diseases, we conducted a
scoping review of PROs in cirrhosis. Our goal was to
identify and summarize the PRO domains that may
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serve as candidates for a set of outcomes as part of
quality improvement efforts in cirrhosis.
Materials and Methods
We performed a scoping review. A scoping review is
a variant of a systematic review which aims to identify
and map key concepts with a large body of evidence.(3)
The scoping review methodology can be more appro-
priate than a systematic review when the body of litera-
ture is large, complex, heterogeneous, and without a
prior comprehensive review.(4) We hypothesized that
the literature would already contain signiﬁcant infor-
mation about PROs relevant to cirrhosis, but the arti-
cle may not be explicitly labeled as such.
SEARCH STRATEGY
With the aid of an informationist with expertise in
scoping reviews (J.E.S.), we searched six databases:
Medline, OVID, Cumulative Index to Nursing and
Allied Health Literature, Embase, PsycINFO, and
Cochrane Library. No date restrictions were applied,
and ﬁnal searches were conducted between April 20
and June 1, 2017. The search strategy for each database
is provided in the Supporting Information. Searches
combined a block of terms speciﬁc to disease (i.e., cir-
rhosis and its complications, as well as each liver dis-
ease enumerated) with terminology speciﬁc to PROs
(e.g., patient-reported measures, quality of life, and
patient satisfaction) and with names of published PRO
instruments used in liver disease (e.g., Short Form-36)
abstracted from a prior systematic review.(5) Sentinel
articles were used to validate the search strategy and
provide additional references through looking at
reference lists and conducting citation tracking
searches through the database SCOPUS. Articles
meeting inclusion criteria were also used to citation-
track using Scopus.
STUDY SELECTION
Studies were included if they reported the con-
struction/validation of a PRO instrument for patients
with cirrhosis or if they assessed the clinical variables
that determined responses to established PRO
scales and reported granular data-speciﬁc domains/
responses within the scales. As above, we deﬁned
PRO as patients’ own assessment of their health sta-
tus including symptoms, reports of daily functioning,
quality of life, and satisfaction with health care. For
example, if a study on quality of life provided details
on these domains, it was included; but if it only
reported summary scores from a previously developed
instrument (such as Short Form-36), then it was
excluded.
We only included English-language publications.
We excluded studies focusing on liver transplant,
including those pertaining to patients awaiting liver
transplant or recollecting their condition prior to trans-
plantation. We also excluded studies of children; of
patients with acute liver failure, noncirrhotic chronic
liver disease (including treatment for hepatitis C), or
hepatocellular carcinoma; and that focused on pre–liver
transplant or post–liver transplant experiences.
Seven reviewers independently screened titles and
abstracts for eligibility. Each title was reviewed by at
least two reviewers. The articles excluded by title,
abstract, and after full-text review were recorded. Each
reviewer selected the full-text studies he or she judged
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to be relevant or unclear. These studies were included
in a ﬁnal grouping where selection conﬂicts between
the two index reviewers were further adjudicated by
two arbitrators (E.B.T. and M.V.) where unresolved
conﬂicts were settled by a third arbitrator (F.K.).
DATA EXTRACTION AND
ANALYSIS
Included studies were summarized according to
their population, aims, methods, and key ﬁndings. All
survey items and determinants of PRO responses were
aggregated and categorized by two reviewers (E.B.T.,
M.V.). Verbatim duplicates were excluded. Discrepan-
cies with respect to inclusion and categorization were
adjudicated by a third review (F.K.).
Results
POPULATION CHARACTERISTICS
IN INCLUDED STUDIES
Of 5,647 studies screened, 11 studies met our inclu-
sion criteria (Fig. 1). For a description of the included
studies, see Table 1. Of these 11 studies, four were
from the United States,(6-9) two from Denmark,(10,11)
and one each from China, Taiwan, Japan, Spain, and
Italy.(12-16) Overall, these studies enrolled 2,299 (range
11-544) patients. The stage of liver disease was avail-
able for 1,550 (67%), of whom 586 (38%) were Child
A and 964 (62%) were Child B-C. Granular details of
cirrhosis etiology were available for 1,268 (55%)
patients, of whom 643 (51%) had viral hepatitis and
360 (28%) had alcoholic liver disease.
DESCRIPTION OF STUDY AIMS
AND METHODS
HRQOL or PRO Scale Development
Four studies—by Younossi et al.,(9) Gralnek
et al.,(7) Onishi et al.,(14) and Zhang et al.(16)—aimed
to create disease-speciﬁc scales. Three of these studies
only included patients with cirrhosis. The fourth
study included patients with as well as those without
cirrhosis; however, the majority (66%) had cirrhosis in
this study. One study(14) focused exclusively on
patients with ascites. Each study used a deliberate,
stepwise approach to determine the pertinent
domains and questions; these included semistructured
patient interviews to develop themes, separate inter-
views to narrow and reﬁne the questions, and an eval-
uative cohort to demonstrate ﬁnal results which
included an assessment of responsiveness to therapy
(Table 1).
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FIG. 1. Flow diagram of study selection. Abbreviation:
CINAHL, Cumulative Index to Nursing and Allied Health
Literature.
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TABLE 1. Characteristics of Included Studies
Reference Population Evaluated Aims Method Key Findings
Younossi
et al.(9)
133 Ambulatory patients:
CTP A (32%), CTP B
(23%), CTP C (11%),
no cirrhosis (34%).
Cholestatic disease
(23%), “hepatocellular”
(77%).
Develop disease-specific
HRQOL instrument.
Semistructured interviews to
select 156 candidate
instrument items in cohort of
60 patients.
Determined importance of each
item in separate cohort of 75
patients for reduction to 29
items.
Identified six domains: abdominal
symptoms, fatigue, systemic
symptoms, activity, emotional
function, and worry. Scores worsen
with CTP class.
Gralnek et al.(7) 221 ambulatory patients:
CTP A (29%), CTP B
(52%), CTP C (19%).
Viral (51%), alcohol
(16%), cholestatic
(12%).
Develop disease-specific
HRQOL instrument.
Semistructured interviews.
Psychometric analysis.
Content validation.
36 items detailing activities of daily
living, concentration, memory,
sexual functioning, sleep,
loneliness, hopelessness, quality of
social interaction, health distress, and
self-perceived stigma.
Marchesini
et al.(13)
544 patients (ambulatory
and admitted): CTP A
(38%), CTP B (38%),
CTP C (24%). Viral
(64%), alcohol (29%).
Determine clinical variables
associated with HRQOL
(SF-36 and NHP).
Cross-sectional survey
responses. Results
compared to age-matched
and sex-matched healthy
controls.
The two most important clinical variables
associated with HRQOL were CTP and
muscle cramps. The presence of HE,
pruritus, ascites, diuretics,
hospitalization, and comorbidities
affected HRQOL subscales.
Chatrath et al.(6) 150 ambulatory patients:
CTP A (29%), CTP B
(47%), CTP C (24%).
Viral (42%), alcohol
(22%).
Determine impact of cramps
on HRQOL (using CLDQ).
Cross-sectional survey
responses and clinical
assessment.
Cramp severity correlates with CLDQ
score. Cramps associated with worse
scores in all CLDQ subscales but
worry.
Tsai et al.(12) 49 hospitalized patients:
CTP A (6%), CTP B
(43%), CTP C (51%).
Alcohol (59%), viral
(35%).
Determine frequency of
physical and
psychological symptoms.
Semistructured interviews.
Rank ordering by frequency.
Content validation.
Physical and psychological symptoms
are highly correlated. Abdominal
symptoms and worry were the most
severe physical and psychological
domains, respectively.
Roman et al.(15) 118 ambulatory patients:
CTP A (62%), CTP B
(34%), CTP C (4%).
Alcohol (62%), viral
(36%).
Determine relationship
between falls and
HRQOL
(using SF-36).
Cross-sectional survey
responses and clinical
assessment for cognitive
dysfunction.
Physical components of HRQOL are most
associated with cognitive dysfunction
and hyponatremia. Mental compo-
nents of HRQOL are most associated
with falls.
Vaughn-Sandler
et al.(8)
149 ambulatory patients:
CTP A (58%), CTP B
(36%), CTP C (5%).
Viral (34%), alcohol
(12%).
Determine prevalence and
impact of stigma.
Cross-sectional survey
responses to questions on
stigma abstracted from
multiple surveys with
opportunity for free-text
response.
Stigma is associated with lower QOL,
depression, lower likelihood of seeking
medical care, and less social support.
Onishi et al.(14) 175 ambulatory patients
evaluated before and
after ascites therapy: CTP
A (12%), CTP B (50%),
CTP C (38%).
Develop ascites-specific
symptom scale.
Semistructured interviews with
psychometric analysis.
Longitudinal assessment for
changes following treatment.
Seven-question scale that correlates with
severity of ascites, SF-36 scores, and
response to treatment.
Mikkelsen
et al.(10,11)
11 ambulatory patients with
alcoholic cirrhosis and
HE.
To identify conditions that
limit or support coping
with physical and
psychological problems.
Semistructured interviews
before and after a coping
and physical activity group
intervention.
Patients feel responsible to and seek
acknowledgment/positive attitudes
from their clinicians, find it difficult to
seek help for alcohol relapse. The
intervention improves patient
assessments of self-control,
community, and strength.
Ying et al.(16) 464 ambulatory patients:
unknown CTP and
etiology.
To develop the LC-PROM, a
cirrhosis-specific PRO
scale that addresses all
physical symptoms,
psychological feelings,
daily activities, and
therapeutic status.
Semistructured interviews with
10 patients, followed by item
refinement by another 10
patients. Item reduction
performed in a sample of
200 subjects (150 with
cirrhosis). Test performance
in 464 patients with cirrhosis
and 112 controls.
LC-PROM consists of 55 items which
include questions to obtain information
about treatment satisfaction,
compliance, and drug side effects.
Abbreviations: CLDQ, Chronic Liver Disease Questionnaire; CTP, Child-Turcotte-Pugh; HE, hepatic encephalopathy; LC-PROM,
Liver Cirrhosis Patient-Reported Outcome Measure; NHP, Nottingham Health Proﬁle; QOL, quality of life; SF-36 5 Short-Form-36.
TAPPER ET AL. HEPATOLOGY, June 2018
2378
Qualitative Analysis
Four studies described the results of qualitative anal-
yses where patients were asked open-ended questions
about their experiences. In three cases, these were per-
formed in focus groups with semistructured interviews.
Tsai et al. interviewed patients and asked them to
rank-order the most important physical and psycho-
logical components of cirrhosis.(12) Over the course of
two articles,(10,11) Mikkelsen et al. described the results
of patient interviews focusing on the conditions that
limit or support coping with physical and psychological
problems before and after a group-therapy interven-
tion. Vaughn-Sandler et al. mailed surveys with ques-
tions and opportunities for free-text responses to
capture the rate and impact of feelings of stigma.(8)
Impact of Clinical Variables on PRO
Domains
Cross-sectional survey studies by Marchesini
et al.,(13) Chatrath et al.,(6) and Roman et al.(15) evalu-
ated the impact of clinical variables on domains
of established PRO scales including the Chronic
Liver Disease Questionnaire, Short Form-36, and
Nottingham Health Proﬁle, respectively. Roman et al.
were speciﬁcally interested in the impact of falls and
cognitive dysfunction, and Chatrath et al. focused
exclusively on the impact of muscle cramps. Marche-
sini et al. explored several clinical variables and used
regression techniques to determine the factors inde-
pendently associated with suboptimal PROs.
CATEGORIZED STUDY FINDINGS
Overall, the 11 studies yielded 259 items speciﬁc to
patients with cirrhosis. After removing duplicates, 152
unique items were isolated (Supporting Information).
Each could be categorized into one of seven broader
domains (physical symptoms, physical function, men-
tal health, general function, cognition, social life, and
satisfaction with care) as well as 52 subdomains (Fig.
2). The physical health domain had the most subdo-
mains (e.g., abdominal pain, appearance, dizziness).
Examples of the mental health domain included
depression and alcohol abuse, the function domain
included items regarding career and daily activities, the
social life domain dealt with stigma and isolation, the
satisfaction with care domain touched on items relating
to medication side effect concerns and the quality of
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FIG. 2. Domains and subdomains of PROs in cirrhosis. Abbreviation: HE, hepatic encephalopathy.
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the patient–doctor relationship, and, ﬁnally, the cogni-
tion domain included items on concentration and for-
getfulness, among others. In many cases, multiple
items referred to the same subdomain; e.g., multiple
questions covered material pertinent to abdominal
pain, bloating, and sexual function. There were many
ways of asking about, for example, the abdominal pain
or itching subdomains of physical health. In the
Supporting Information, we provide representative
example items for each subdomain, e.g., “I was
annoyed at abdominal pain and indigestion” (abdomi-
nal pain from Zhang et al.(16)) and “How much have
you been troubled by itching during the last two
weeks?” (pruritis from Younossi et al.(5)).
Multiple studies evaluated whether speciﬁc variables
were associated with signiﬁcant differences in the
scores of PRO scales such as the Short Form-36, Not-
tingham Health Proﬁle, and Chronic Liver Disease
Questionnaire (Table 2). Twelve variables were
identiﬁed based on the review of these studies. These
included clinical factors (etiology and severity of liver
disease, cognitive dysfunction and hepatic encephalop-
athy, ascites, comorbidities, medication burden, loop
diuretics, hospitalization) and patient-reported symp-
toms (cramps, pruritis, falls)
Discussion
In this scoping review, we systematically identiﬁed
152 distinct PROs reported by patients with cirrhosis.
We then distilled them into a set of seven major
domains and 52 subdomains. These data from 11
studies reﬂect the experiences of 2,299 patients from
seven countries across the spectrum of disease etiology
and severity. Whereas any one study’s results may not
generalize to another context, this scoping review pro-
vides a comprehensive list of PROs that are applicable
TABLE 2. Domains of Established HRQOL Scales Impacted by Clinical Variables
Scale/
Study
Domains
Affected
by Clinical
Variables
Clinical Variables
Ascites Comorbidity
Severity of
Disease
Cognitive
Dysfunction
Pill
Burden
Disease
Etiology Falls
Hospital
Admits HE
Loop
Diuretic
Muscle
Cramps Pruritis
SF-36 General Health  – –  – X  –  –  
Vitality  –   – X  –    
Physical Roles  –    X      
Physical
Functioning
 –    X      
Emotional Roles  – –   X  –    
Mental Health  – –  – X  – –   
Social
Functioning
– –   – X  – – –  
Bodily Pain  – – –  X   –   –
NHP Energy  –  X  X X   –  
Sleep  – – X – X X –  –  
Pain – – – X  X X – – –  
Emotional
Reactions
  – X – X X – – –  
Social Isolation   – X – X X – – –  
Physical
Mobility
   X  X X     
CLDQ Fatigue X X X X X X X X X X  X
Activity X X X X X X X X X X  X
Systemic
Symptoms
X X X X X X X X X X  X
Abdominal
Symptoms
X X X X X X X X X X  X
Emotional
Function
X X X X X X X X X X  X
Vaughn-
Sandler
et al.(8)
Stigma X X X X X  X X X X  X
, statistically signiﬁcant association; –, lack of an association; X, the impact of this variables was not assessed for that particular scale/
study.
Abbreviations: CLDQ, Chronic Liver Disease Questionnaire; HE, hepatic encephalopathy; NHP, Nottingham Health Proﬁle; SF-36,
Shortform-36.
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to most patients with cirrhosis seen in different health
care settings.
These data extend the literature on PROs in cirrho-
sis in two principal ways. First, our goal was to identify
a broad range of PROs that matter to our patients.
Many disease-speciﬁc HRQOL instruments (e.g.,
Chronic Liver Disease Questionnaire(9) and Liver Dis-
ease Quality of Life(7)) have already been developed for
patients with cirrhosis. Other nonspeciﬁc tools, such as
the Patient-Reported Outcomes Measurement Infor-
mation System, have been validated in populations
with cirrhosis.(17) Indeed (and not surprisingly), the
broader domains that we identiﬁed map well with the
domains in existing HRQOL instruments. Our review
also found many additional items and subdomains that
were not included in previous HRQOL tools. Whereas
HRQOL instruments reliably capture the patient’s val-
ues, preferences, and responses to therapeutic interven-
tions, they do not necessarily speak to other PRO
domains such as symptom status, function, satisfaction
with care, and adherence to medication.(18) Further-
more, in contrast to the development of psychometric
indices, for the purpose of quality improvement, it is
important to identify measures that are sufﬁciently
granular to inform speciﬁc therapeutic needs (i.e., as
relates to frailty or sexual dysfunction) and are respon-
sive to therapeutic interventions (such as control of
ascites).
Second, our review also identiﬁed 12 variables that
had a statistically signiﬁcant and clinically meaningful
impact on established HRQOL scales. Although some
of these factors were PROs (pruritis, cramps), most
were clinician-reported features of cirrhosis that signif-
icantly impacted PROs. The latter may either serve as
surrogate outcome measures (such as falls, hospitaliza-
tion) or variables for case-mix risk adjustment of
PROs (such as the etiology of liver disease and the
presence of comorbid conditions).
To build on this study, we suggest two next steps.
One, these PROs can serve as important measures for
clinical care that many physicians may want to explore
with their patients. Answers to many questions that
may often go unasked, about, for example, falls, pruri-
tis, or sexual function, have the capacity to modify clin-
ical management in meaningful ways. Two, these
PROs will serve as potential candidates for outcome-
based quality measures. These items will serve as can-
didate outcome measures for an upcoming two-round
modiﬁed Delphi panel process for ranking and selec-
tion by a group of content experts. Thereafter, a speci-
ﬁcation process will follow to convert these ﬁndings
into discrete measures with clear numerators, denomi-
nators, and denominator exclusions that can be imple-
mented into clinical care and followed longitudinally.
A similar PRO identiﬁcation process was recently
employed by the International Consortium for Health
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FIG. 3. Overview of the process translating PROs into quality measures. The goal of the Practice Metrics Committee of the
American Association for the Study of Liver Diseases is to create a registry that tracks clinical outcomes and PROs. To achieve this
goal, the committee is developing a platform that allows for the integration of clinical data (e.g., etiology, disease severity, and comor-
bid illnesses) with PROs obtained during a clinical visit in the electronic health record. The work described in this article is the crucial
ﬁrst step where the key PROs for patients with cirrhosis have been collected from the literature. Our next step is to reﬁne and specify
the PROs (i.e., how they will be measured) during patient focus groups and a modiﬁed Delphi process with expert hepatologists.
Abbreviation: EHR, electronic health record.
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Outcomes Measurement group.(19,20) As this group
has identiﬁed, new reporting standards may increase
the demands for data collection on frontline providers.
Implementation is an unresolved challenge for the
growing experience with PRO sets.(19-21) In addition
to the work on PRO identiﬁcation, implementation
efforts designed with sensitivity to clinician workﬂow
are necessary. The optimal quality measure is clinically
meaningful, standardized, and easily measured while
neither overburdening the frontline clinician (and
patient) nor increasing the costs of health care delivery.
Realizing the goal of integrating a set of PRO assess-
ments in routine clinical practice will require designing
items with responses that are easily abstracted from
existing data and leveraging the functionality of elec-
tronic health records. In Fig. 3, we summarize the
work to date and outline the remaining steps needed to
achieve our goals.
These data must be interpreted in the context of the
study design. First, given the inclusion criteria for the
selected studies, these data apply to pretransplant adult
patients with cirrhosis; generalizability to posttrans-
plant or pediatric patients is unclear. Second, the list of
52 subdomains may be reduced further if some factors
are found to be duplicative or equivalent by patients.
For example, the term “bleeding episodes” may sufﬁce
for hematemesis, melena, and epistaxis. Third, the rel-
ative importance of speciﬁc domains is certain to
change with the patient’s clinical context. The patient
with Child A cirrhosis may beneﬁt from surveys that
focus on speciﬁc domains and subdomains such as
mental health (sexual function, alcohol, and stigma),
whereas those with Child C may need to be asked dif-
ferent questions (such as adherence, isolation, and
caregiver burden).
In conclusion, the symptoms and preferences
expressed by patients with cirrhosis are equal in impor-
tance to their clinical outcomes. Well-deﬁned quality
indicators based on processes of care have been deﬁned
to facilitate improved clinical outcomes. Similar indica-
tors are lacking for PROs. This scoping review identi-
ﬁed a large existing set of PRO concepts, which may
now be translated into usable measures to support
quality improvement in cirrhosis.
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